Skip to main content

Table 2 Adjusted sub-distribution hazard ratios for developing atrial fibrillation in breast cancer surgery survivors compared to the noncancer general population by age categories

From: Mid- and long-term risk of atrial fibrillation among breast cancer surgery survivors

 

Age group

Subjects (N)

Case (n)

IR per 1000 person-years

Model 1 (Crude)

sHR (95% CI)

Model 2

sHR (95% CI)

Model 3

sHR (95% CI)

Main analysis

All ages

Noncancer

566,160

5,271

1.76

1 (Ref.)

1 (Ref.)

1 (Ref.)

Breast cancer

113,232

1,166

2.01

1.14 (1.07–1.22)

1.15 (1.08–1.23)

1.06 (1.00–1.13)

18–39

Noncancer

61,325

91

0.27

1 (Ref.)

1 (Ref.)

1 (Ref.)

Breast cancer

12,265

51

0.78

2.94 (2.09–4.15)

2.95 (2.10–4.16)

2.79 (1.98–3.94)

40–50

Noncancer

202,435

684

0.63

1 (Ref.)

1 (Ref.)

1 (Ref.)

Breast cancer

40,487

171

0.81

1.28 (1.09–1.52)

1.29 (1.09–1.53)

1.22 (1.03–1.45)

51–65

Noncancer

235,670

2,123

1.71

1 (Ref.)

1 (Ref.)

1 (Ref.)

Breast cancer

47,134

497

2.06

1.21 (1.10–1.33)

1.22 (1.10–1.34)

1.13 (1.03–1.25)

≥ 66

Noncancer

66,730

2,373

7.31

1 (Ref.)

1 (Ref.)

1 (Ref.)

Breast cancer

13,346

447

7.08

0.97 (0.88–1.07)

0.98 (0.89–1.09)

0.90 (0.81–0.99)

P for interaction

   

< 0.001

< 0.001

< 0.001

3–year landmark analysis

All ages

Noncancer

546,453

3,609

1.94

1 (Ref.)

1 (Ref.)

1 (Ref.)

Breast cancer

107,153

777

2.17

1.12 (1.04–1.21)

1.13 (1.05–1.22)

1.05 (0.97–1.14)

18–39

Noncancer

59,817

60

0.28

1 (Ref.)

1 (Ref.)

1 (Ref.)

Breast cancer

11,617

31

0.76

2.75 (1.78–4.24)

2.76 (1.79–4.26)

2.62 (1.70–4.05)

40–50

Noncancer

196,863

472

0.69

1 (Ref.)

1 (Ref.)

1 (Ref.)

Breast cancer

38,727

117

0.89

1.28 (1.05–1.57)

1.29 (1.06–1.58)

1.23 (1.00–1.50)

51–65

Noncancer

227,856

1,516

1.97

1 (Ref.)

1 (Ref.)

1 (Ref.)

Breast cancer

44,665

328

2.22

1.13 (1.00–1.27)

1.14 (1.01–1.28)

1.06 (0.94–1.20)

≥ 66

Noncancer

61,917

1,561

8.04

1 (Ref.)

1 (Ref.)

1 (Ref.)

Breast cancer

12,144

301

8.06

1.00 (0.89–1.14)

1.02 (0.90–1.15)

0.93 (0.82–1.05)

P for interaction

   

< 0.001

< 0.001

< 0.001

5-year landmark analysis

All ages

Noncancer

546,453

1,918

2.11

1 (Ref.)

1 (Ref.)

1 (Ref.)

Breast cancer

107,153

388

2.25

1.07 (0.96–1.19)

1.08 (0.96–1.19)

1.00 (0.90–1.12)

18–39

Noncancer

59,817

28

0.25

1 (Ref.)

1 (Ref.)

1 (Ref.)

Breast cancer

11,617

12

0.59

2.32 (1.18–4.56)

2.33 (1.18–4.57)

2.22 (1.13–4.37)

40–50

Noncancer

196,863

265

0.79

1 (Ref.)

1 (Ref.)

1 (Ref.)

Breast cancer

38,727

65

1.01

1.28 (0.98–1.68)

1.29 (0.98–1.69)

1.23 (0.94–1.62)

51–65

Noncancer

227,856

812

2.18

1 (Ref.)

1 (Ref.)

1 (Ref.)

Breast cancer

44,665

163

2.31

1.06 (0.90–1.25)

1.06 (0.90–1.26)

1.00 (0.84–1.18)

≥ 66

Noncancer

61,917

813

9.08

1 (Ref.)

1 (Ref.)

1 (Ref.)

Breast cancer

12,144

148

8.70

0.96 (0.80–1.14)

0.96 (0.81–1.15)

0.89 (0.74–1.06)

P for interaction

   

0.041

0.041

0.024

  1. Landmark analysis was conducted to estimate AF risk in individuals who were event-free at specific time points (landmark time), 3 and 5 years post-breast cancer diagnosis, respectively
  2. Model 2: adjusted for age, income status, and residential location
  3. Model 3: adjusted for Model 2 + hypertension, type 2 diabetes, dyslipidemia, coronary heart disease, congestive heart failure, chronic kidney disease, and chronic obstructive pulmonary disease
  4. IR Incidence rate, PYs Person-years, sHR Sub-distribution hazard ratio, CI Confidence interval
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us